Curis, Inc. (CRIS)
Market Cap | 28.75M |
Revenue (ttm) | 10.26M |
Net Income (ttm) | -45.48M |
Shares Out | 8.47M |
EPS (ttm) | -7.80 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 44,904 |
Open | 3.240 |
Previous Close | 3.080 |
Day's Range | 3.188 - 3.560 |
52-Week Range | 3.050 - 17.490 |
Beta | 3.36 |
Analysts | Strong Buy |
Price Target | 23.00 (+577.47%) |
Earnings Date | Feb 6, 2025 |
About CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with r... [Read more]
Financial Performance
In 2023, Curis's revenue was $10.02 million, a decrease of -1.37% compared to the previous year's $10.16 million. Losses were -$47.41 million, -16.34% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price forecast is $23.0, which is an increase of 577.47% from the latest price.
News
Curis Announces Additional Data from TakeAim Leukemia Study
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...
Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer...
Curis Provides Third Quarter 2024 Business Update
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
LEXINGTON, Mass. , Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
LEXINGTON, Mass. , Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...
Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
Symposium hosted by Eric S. Winer, MD, and Grzegorz S.
Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference
LEXINGTON, Mass. , Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh...
Curis to Present at Upcoming Healthcare Conferences in September
LEXINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis, Inc. (CRIS) Q2 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President and CEO Jonathan Zung - Chie...
Curis Provides Second Quarter 2024 Financial and Operating Update
EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
LEXINGTON, Mass. , July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis to Present at Upcoming Healthcare Conference in July
LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass. , July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...
Curis to Present Updated Data from the TakeAim Leukemia Study
LEXINGTON, Mass. , May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...
Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President & CEO Robert Martell - Chief Scientific Officer Con...
Curis Provides First Quarter 2024 Business Update
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
LEXINGTON, Mass. , April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh...
Curis to Present at Upcoming Healthcare Conferences in April
LEXINGTON, Mass. , April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...
Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript
Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript
Curis Provides Fourth Quarter 2023 Business Update
Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call toda...
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
LEXINGTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
LEXINGTON, Mass. , Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
LEXINGTON, Mass. , Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis Announces Three Presentations at ASH
LEXINGTON, Mass. , Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
LEXINGTON, Mass. , Dec. 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...